Charles Scott Jennisch, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 6921 Hickman Rd Ste 2327, Urbandale, IA 50322 Phone: 515-270-2242 |
Scott Eastin, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 6921 Hickman Rd # 2327, Urbandale, IA 50322 Phone: 515-271-6300 Fax: 515-271-6311 |
Sharon L Koele, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 2327 70th St., Iowa Psychiatry, Llc, Urbandale, IA 50322 Phone: 515-270-2242 Fax: 515-777-1950 |
Dr. Ara J Robinson, D.O. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 6921 Hickman Rd, Ste 2327, Urbandale, IA 50322 Phone: 515-270-2242 |
Dr. Charles Vincent Wadle, D.O. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 2500 82nd Pl, Urbandale, IA 50322 Phone: 515-270-1344 |
News Archive
Kansas Gov. Sam Brownback announced a major overhaul of the state's Medicaid program today, which would put nearly all Medicaid recipients into private, managed-care plans. While low-income families are currently in such plans, elderly and disabled Kansans receive care through a fee-for-service system.
Researchers at Tufts University have elucidated a mechanism by which the "good" bacteria that reside in our gastrointestinal tract can help protect us from inflammation, and how their disruption (dysbiosis) can increase the susceptibility of the liver to more harmful forms of disease.
Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today celebrated its 10th year anniversary in South Korea by announcing a strategic alliance with the Seoul National University Hospital (SNUH) as part of its unique Prime Site program. SNUH is Quintiles' second Prime Site in Asia, adding to six other existing sites located in the United States, Europe and Africa.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.
Southern Research Institute today announced a new service offering - a novel in vitro 12-cell line panel assay designed to predict drug activity and improve the success rate of drugs tested in xenograft models.
› Verified 3 days ago